Asian Pacific Journal of Cancer Prevention

  • 제13권5호
  • /
  • Pages.2009-2014
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Tas13D Inhibits Growth of SMMC-7721 Cell via Suppression VEGF and EGF Expression

  • He, Huai-Zhen (School of Medicine, Xi'an Jiaotong University) ;
  • Wang, Nan (School of Medicine, Xi'an Jiaotong University) ;
  • Zhang, Jie (School of Medicine, Xi'an Jiaotong University) ;
  • Zheng, Lei (School of Medicine, Xi'an Jiaotong University) ;
  • Zhang, Yan-Min (School of Medicine, Xi'an Jiaotong University)
  • 발행 : 2012.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Taspine, isolated from Radix et Rhizoma Leonticis has demosntrated potential proctiective effects against cancer. Tas13D, a novel taspine derivative synthetized by structure-based drug design, have been shown to possess interesting biological and pharmacological activities. The current study was designed to evaluate its antiproliferative activity and underlying mechanisms. Methods: Antiproliferative activity of tas13D was evaluated by xenograft in athymic mice in vivo, and by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and cell migration assays with human liver cancer (SMMC-7721) cell lines in vitro. Docking between tas13D and VEGFR and EGFR was studied by with a Sybyl/Surflex module. VEGF and EGF and their receptor expression was determined by ELISA and real-time PCR methods, respectively. Results: Our present study showed that tas13D inhibited SMMC-7721 xenograft tumor growth, bound tightly with the active site of kinase domains of EGFR and VEGFR, and reduced SMMC-7721 cell proliferation (IC=34.7 ${\mu}mol/L$) and migration compared to negative controls. VEGF and EGF mRNAs were significantly reduced by tas13D treatment in a dose-dependent manner, along with VEGF and EGF production. Conclusion: The obtained results suggest that tas13D inhibits tumor growth and cell proliferation by inhibiting cell migration, downregulating mRNA expression of VEGF and EGF, and decreasing angiogenic factor production. Tas13D deserves further consideration as a chemotherapeutic agent.

키워드

참고문헌

  1. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature, 438, 932-6. https://doi.org/10.1038/nature04478
  2. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, et al (2006). Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer, 119, 2557-66. https://doi.org/10.1002/ijc.22221
  3. Fayad W, Fryknas M, Brnjic S, et al (2009). Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters. Plos One, 4, e7238. https://doi.org/10.1371/journal.pone.0007238
  4. Folkman J (1992). Introduction angiogenesis and cancer, Semin. Cancer Biol, 3, 47-8.
  5. Han SW, Hwang PG, Chung DH, et al (2005). Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer, 113, 109-15. https://doi.org/10.1002/ijc.20550
  6. Harichand-Herdt S, Ramalingam SS (2008). Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. Semin Thorac Cardiovasc Surg, 20, 217-23. https://doi.org/10.1053/j.semtcvs.2008.09.005
  7. Hirsch FR, Varella-Garcia M, Bunn PA, et al (2006). Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced nonsmall-cell lung cancer. J Clin Oncol, 24, 5034-42. https://doi.org/10.1200/JCO.2006.06.3958
  8. Ishiwata I, Sudo T, Kiguchi K, et al (1999). Tumor angiogenesis factors produced by cancer cells. Hum Cell, 12, 37-46.
  9. Kelly TR, Xie RL (1998). Total synthesis of taspine. J Org Chem, 63, 8045-8. https://doi.org/10.1021/jo981099j
  10. Kerbel RS (2000). Tumour angiogenesis: past, present and the near future. Carcinogenesis, 21, 505-15. https://doi.org/10.1093/carcin/21.3.505
  11. Kim ES, Khuri FR, Herbst RS (2001). Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol, 13, 506-13. https://doi.org/10.1097/00001622-200111000-00014
  12. Klein S, Levitzki A (2009). Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol, 21, 185-93. https://doi.org/10.1016/j.ceb.2008.12.006
  13. Li ZH, Zhao RJ, Wu XH, et al (2005). Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J, 19, 1979-85.
  14. Liang GB, Zhang GP, Jin HM (2005). Influence of basic fibroblast growth factor on ECV304 cell migration. Chin J Pathophysiol, 21, 16-20.
  15. Lin CM, Chang H, Chen YH, et al (2006). Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int Immunopharmacol, 6, 1690-8. https://doi.org/10.1016/j.intimp.2006.07.003
  16. Martinez A (2006). A new family of angiogenic factors. Cancer Lett, 36, 157-63
  17. Mou J, Fang H, Jing F, et al (2009). Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors. Bioorg Med Chem, 17, 4666-73. https://doi.org/10.1016/j.bmc.2009.04.056
  18. Mu H, Ohashi R, Yan S, et al (2006). Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res, 70, 146-57. https://doi.org/10.1016/j.cardiores.2006.01.015
  19. Myoung H, Hong SP, Yun PY, et al (2003). Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Sci, 94, 215-20. https://doi.org/10.1111/j.1349-7006.2003.tb01422.x
  20. Naruse I, Ohmori T, Ao Y, et al (2002). Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFRexpressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer, 98, 310-5. https://doi.org/10.1002/ijc.10173
  21. Perdue GP, Blomster RN, Blake DA, et al (1979). South American plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci, 68, 124-6. https://doi.org/10.1002/jps.2600680145
  22. Shimamura M, Hazato T, Ashino H, et al (2001).Inhibition of angiogenesis by humulone, a bitter acid from beer hop. Biochem Biophys Res Commun, 289, 220-4. https://doi.org/10.1006/bbrc.2001.5934
  23. Shyu KG, Tsai SC, Wang BW, et al (2004). Saikosaponin C induces endothelial cells growth, migration and capillary tube formation. Life Sci, 76, 813-26. https://doi.org/10.1016/j.lfs.2004.10.003
  24. Sikander M, Malik S, Yadav D, et al (2011). Cytoprotective activity of a trans-chalcone against hydrogen peroxide induced toxicity in hepatocellular carcinoma (HepG2) cells. Asian Pac J Cancer P, 12, 2513-6.
  25. Yu T, Hou FG, Liu MM, et al (2012). Norcantharidin antiangiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer. Asian Pac J Cancer P, 13, 499-503. https://doi.org/10.7314/APJCP.2012.13.2.499
  26. Uchida C, Haas TL (2009). Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Curr Pharm Des, 15, 411-21. https://doi.org/10.2174/138161209787315800
  27. Yancopoulos GD, Davls S, Gale NW, et al (2000). Vascularspecific growth factors and blood vessel formation. Nature, 407, 242-8. https://doi.org/10.1038/35025215

피인용 문헌

  1. Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells vol.34, pp.5, 2013, https://doi.org/10.1007/s13277-013-0825-9
  2. : An Overview of Chemistry and Bioactivity vol.2014, pp.1741-4288, 2014, https://doi.org/10.1155/2014/684508